• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND VENA SEAL CLOSURE SYSTEM; AGENT, OCCLUDING, VASCULAR, PERMANENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND VENA SEAL CLOSURE SYSTEM; AGENT, OCCLUDING, VASCULAR, PERMANENT Back to Search Results
Device Problem Biocompatibility (2886)
Patient Problems Granuloma (1876); Insufficient Information (4580)
Event Date 10/01/2021
Event Type  Injury  
Manufacturer Narrative
Title: cyanoacrylate granuloma after cyanoacrylate closure of incompetent saphenous veins author: nuttawut sermsathanasawadi, kanin pruekprasert, khamin chinsakchai journal: dermatologic surgery year: 2021 vol/issue: 47(10) ref: 10.1097/dss.0000000000003183.If information is provided in the future, a supplemental report will be issued.
 
Event Description
A journal article was submitted detailing a retrospective observational study to evaluate the incidence, the risk factors for, and the management of cyanoacrylate granuloma (cag) after cac of incompetent saphenous veins in patients with chronic venous disease.126 veins from 101 patients were included in the study.Bilateral cac was performed in 25 patients.Medtronic¿s venaseal closure system was used.All patients had undergone duplex ultrasound scanning before saphenous vein ablation.Patients were treated per the manufacturer¿s instructions for use (ifu) for treatment of saphenous veins.Recapture of the delivery catheter before withdrawal was not performed in all patients.Occlusion of the saphenous vein was verified by ultrasound examination immediately after the procedure.Neither compression stockings nor compression bandages were applied in patients with ceap classification c2 (varicose vein).In patients with ceap c3-c6 , patients were asked to continue using compression stockings or compression bandages the same as they had been using them before surgery.Patients were instructed to ambulate frequently and to resume their normal activities at their own discretion.Patients were followed up at the hospital at 1 week, 1 month, 3 months, and 12 months after the procedure for clinical assessment.Duplex ultrasound evaluation was performed at 1 week, 1 month, and 12 months after cac.Complete closure of the saphenous vein after cac was defined as closure along the entire treated saphenous vein without a patent segment greater than 5 cm in length.Preprocedural and postprocedural venous clinical severity score (vcss) and complications were recorded by physicians at each visit.If cag occurred, the onset, duration of symptoms, and management were collected.The occlusion rate was 100%, 99.2%, and 97.8% at the 1-week, 1-month, and 1-year follow-up, respectively.Seven patients who had persistent venous symptoms from tributary varicosity were treated with foam sclerotherapy at 3 months after cac.Cyanoacrylate granuloma occurred in 3 of 101 patients, in 3 of 126 (2.3%) limbs, and in 3 of 126 (2.3%) treated saphenous veins.Patients with cag presented with granuloma and abscess at the puncture site at 3, 4, and 5 months after cac.All cag occurred after cac of gsv.All patients were treated with incision, drainage, and removal of the glue foreign body.All patients received amoxicillin and clavulanic acid 1 gram twice daily for 7 days.Pus cultures showed no growth for bacterial infection.No recurrent granuloma was observed during the study period.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VENA SEAL CLOSURE SYSTEM
Type of Device
AGENT, OCCLUDING, VASCULAR, PERMANENT
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
EI 
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
EI  
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key13617778
MDR Text Key286228444
Report Number9612164-2022-00811
Device Sequence Number1
Product Code PJQ
Combination Product (y/n)N
Reporter Country CodeTH
PMA/PMN Number
P140018
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 02/28/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 02/01/2022
Initial Date FDA Received02/28/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age64 YR
Patient SexFemale
-
-